Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMET: Long-term Safety of AXS-05 in MDD
NCT04039022Phase 3Completed
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Jul 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dextromethorphan + bupropion in major depressive disorder (MDD), sponsored by Axsome Therapeutics, Inc.. Started Jul 2019; status: completed.
02
Drugs
dextromethorphan + bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04039022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04039022.